Editing Life extension (section)

====Within the field====
{{See also|Biogerontology}}
There is a need and research into the development of aging [[biomarker]]s such as the [[epigenetic clock]] "to assess the ageing process and the efficacy of interventions to bypass the need for large-scale longitudinal studies".<ref name="Campisi-2019"/><ref name="Zhavoronkov-2019">{{cite journal | vauthors = Zhavoronkov A, Mamoshina P, Vanhaelen Q, Scheibye-Knudsen M, Moskalev A, Aliper A | title = Artificial intelligence for aging and longevity research: Recent advances and perspectives | journal = Ageing Research Reviews | volume = 49 | pages = 49–66 | date = January 2019 | pmid = 30472217 | doi = 10.1016/j.arr.2018.11.003 | s2cid = 53755842 | doi-access = free }}</ref> Such biomarkers may also include in vivo [[brain imaging]].<ref>{{cite journal | vauthors = Ingram DK, Chefer S, Matochik J, Moscrip TD, Weed J, Roth GS, London ED, Lane MA | display-authors = 6 | title = Aging and caloric restriction in nonhuman primates: behavioral and in vivo brain imaging studies | journal = Annals of the New York Academy of Sciences | volume = 928 | pages = 316–326 | date = April 2001 | issue = 1 | pmid = 11795523 | doi = 10.1111/j.1749-6632.2001.tb05661.x | s2cid = 35478202 }}</ref>

Reviews sometimes include structured tables that provide systematic overviews of intervention/drug candidates with a review calling for integrating "current knowledge with multi-omics, health records, and drug safety data to predict drugs that can improve health in late life" and listing [[research question|major outstanding questions]].<ref name="Donertas-2019"/> [[Biological database]]s of prolongevity drug candidates under research as well as of potential gene/protein targets include GenAge, DrugAge and Geroprotectors.<ref name="Donertas-2019"/><ref>{{cite journal | vauthors = Cardoso AL, Fernandes A, Aguilar-Pimentel JA, de Angelis MH, Guedes JR, Brito MA, Ortolano S, Pani G, Athanasopoulou S, Gonos ES, Schosserer M, Grillari J, Peterson P, Tuna BG, Dogan S, Meyer A, van Os R, Trendelenburg AU | display-authors = 6 | title = Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases | journal = Ageing Research Reviews | volume = 47 | pages = 214–277 | date = November 2018 | pmid = 30071357 | doi = 10.1016/j.arr.2018.07.004 | s2cid = 51865989 | doi-access = free | hdl = 10807/130553 | hdl-access = free }}</ref>

A review has pointed out that the approach of "'epidemiological' comparison of how a low versus a high consumption of an isolated macronutrient and its association with health and mortality may not only fail to identify protective or detrimental nutrition patterns but may lead to misleading interpretations". It proposes a multi-pillar approach, and summarizes findings towards constructing – multi-system-considering and at least age-personalized dynamic – refined longevity diets. Epidemiological-type observational studies included in meta-analyses should according to the study at least be complemented by "(1) basic research focused on lifespan and healthspan, (2) carefully controlled clinical trials, and (3) studies of individuals and populations with record longevity".<ref name="Longo-2022">{{cite journal | vauthors = Longo VD, Anderson RM | title = Nutrition, longevity and disease: From molecular mechanisms to interventions | language = English | journal = Cell | volume = 185 | issue = 9 | pages = 1455–1470 | date = April 2022 | pmid = 35487190 | pmc = 9089818 | doi = 10.1016/j.cell.2022.04.002 }}</ref>